R-ketoprofen OTC product development pact with Sepracor discontinued by Bayer.

BAYER WILL NOT PURSUE OTC R-KETOPROFEN PRODUCT DEVELOPMENT with Sepracor, the companies announced in separate press releases the week of Dec. 4. Bayer's decision not to pursue R-ketoprofen was based on the conclusion that the project did not fit its strategic research and development focus. The decision followed the completion of early clinical trials on the compound.